AQST is trading at $4.24 (5.2% down) as the stock continues to slide following a sharp drop on June 25, 2026, driven by regulatory and legal concerns.
- Investor sentiment remains pressured by the stalled FDA trajectory for the company's allergy drug, Anaphylm.
- Mounting securities lawsuits are creating a significant legal overhang on the investment case.
- Today's move appears to be an extension of Thursday’s selloff, with no fresh company-specific headlines to counter the downward trend.